This book compiles multidisciplinary efforts to conceptualize the environment in research and clinical setting that creates the fertile ground for the practical utility of personalized medicine decisions and also enables clinical pharmacogenomics for establishing pharmacotyping in drug prescription. Its covers innovative drug formulations and nanotheranostics, molecular imaging and signatures, translational nanomedicine and informatics, stem cell therapy approaches, modeling and predictability of drug response, pharmacogenetics-guided drug prescription, pediatric drug dosing, pharmacovigilance and regulatory aspects, ethical and cost-effectiveness issues, pharmacogenomics knowledge bases, personal genome sequencing, molecular diagnostics, as well as information-based medicine.
Implementation of Pharmacogenetics in Evidence-Based Medicine. Pharmacotyping-Based Drug Prescription. Pharmacogenetics-Guided Antithrombotic Therapy. Translational Bioinformatics and Systems Biology. Predictive Genomic Signatures. Personalizing Stem Cell Therapeutic Potential. RNAi Nanomedicines. Nanotechnology Advancements for Personalized Medicine. Pharmacogenetics and Pharmacovigilance. Genetic Variability of Cytochrome P450 Drug Metabolizing Enzymes. Developmental Pharmacology and Pediatric Drug Dosing. Functional Mapping of drug response; Predictive molecular signatures; Information-based medicine; Simcyp population-based ADME Simulator. The Coriell Personalized Medicine Collaborative. Drug Bioavailability and Gene Profiling. Safety Assessment in Nanotechnology. In Vivo Pharmacology. Biostatistics and Text Mining. Intersection of Pharmacology, Imaging, and Genetics. Boron Neutron Capture Therapy. Personalized Medicine in Breast Cancer. Personalized Therapy of Metabolic Diseases. Molecular Biomarkers and Imaging. Pharmacogenomics of Drug-Induced Hepatotoxicity. Education Programs for Pharmacogenomics. Computerized Clinical Decision Support Systems for Prescribing; Therapeutic Drug Monitoring. Cost-Effectiveness of Pharmacogenomics; Ethical and Legal Pharmacogenomics Issues.